Bace: Lead Target For Orchestrated Therapy Of Alzheimer's Disease

Bace: Lead Target For Orchestrated Therapy Of Alzheimer's Disease
by Varghese John / / / PDF


Read Online 3.8 MB Download


BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book details the story of the discovery of BACE and its role in AD and comprehensively discusses: - The development of BACE inhibitors as therapeutics for Alzheimer's disease - The research that led to the identification of BACE - New BACE inhibitors currently being clinically tested - ADME (absorption, distribution, metabolism, excretion) and clinical trial designtopics not addressed in current field literature - Cutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery - Other approaches to BACE inhibition based on interaction with the precursor protein APP By enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's researchand inspire new approaches to treatment of AD.

views: 372